|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
Synonyms ![]() |
BAY 94-8862 |
Database Links ![]() |
|
GtoPdb PubChem SID | 252166878 |
PubChem CID | 60150535 |
Search Google for chemical match using the InChIKey | BTBHLEZXCOBLCY-QGZVFWFLSA-N |
Search Google for chemicals with the same backbone | BTBHLEZXCOBLCY |
Search UniChem for chemical match using the InChIKey | BTBHLEZXCOBLCY-QGZVFWFLSA-N |
Search UniChem for chemicals with the same backbone | BTBHLEZXCOBLCY |
Comments |
Finerenone (BAY 94-8862) is a next generation oral, non-steroidal Mineralocorticoid Receptor antagonist which blocks the deleterious effects of aldosterone. Finerenone is currently in clinical Phase IIb development for the treatment of worsening chronic heart failure [2], as well as diabetic nephropathy. |